velagliflozin

a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of diabetes

Also Known As:

2-((4-cyclopropylphenyl)methyl)-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)benzonitrile

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Clark, M: 1 article (04/2018)
2.	Hoenig, M: 1 article (04/2018)
3.	Reiche, D: 1 article (04/2018)
4.	Schaeffer, D J: 1 article (04/2018)
5.	Meier, Alexandra: 1 article (01/2018)
6.	Pollitt, Christopher: 1 article (01/2018)
7.	Reiche, Dania: 1 article (01/2018)
8.	Sillence, Martin: 1 article (01/2018)
9.	Walsh, Donald: 1 article (01/2018)
10.	de Laat, Melody: 1 article (01/2018)

1.	Hyperglycemia 04/01/2018 - "We conclude that velagliflozin is a promising drug, which increases urinary glucose excretion in cats and could thereby be beneficial for the treatment of hyperglycemia."
2.	Hyperinsulinism (Hyperinsulinemia) 01/01/2018 - "This study aimed to determine if velagliflozin reduced hyperinsulinemia and prevented laminitis in insulin-dysregulated ponies fed a challenge diet high in non-structural carbohydrates (NSC). " 01/01/2018 - "The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies."
3.	Hypoglycemia (Reactive Hypoglycemia) 01/01/2018 - "Velagliflozin was well-tolerated, with no hypoglycemia or any clinical signs of adverse effects. "